Program
Pneumococcal 21-Valent Conjugate Vaccine
Also written as “V116”, “PCV21 vaccine” and “PCV21”.
Its studies are mostly in Pneumococcal Infections · Pneumonia, Pneumococcal · Anemia, Sickle Cell, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 110 open or running | phase 3since May 23, 2022 | Nov 18, 2019 | none ahead |
| Sanofi | 77 open or running | phase 3since Oct 10, 2024 | Oct 10, 2024 | Dec 1, 2026phase 3 · NCT06838000 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Nov 18, 2019.
- May 23, 2022Phase 3 study in Pneumococcal InfectionsMerck · NCT05393037 · 313 enrolled · United States, Belgium, Chile and more
- Jun 13, 20222 phase 3 studiesMerck · NCT05420961, NCT05425732
- Jul 12, 2022Phase 3 study in Pneumococcal InfectionsMerck · NCT05464420 · 2,162 enrolled · United States, Austria, Canada and more
- Aug 31, 2022Phase 3 study in Pneumonia, PneumococcalMerck · NCT05526716 · 1,080 enrolled · United States
- Oct 4, 2022Phase 3 study in Pneumococcal InfectionsMerck · NCT05569954 · 1,484 enrolled · Argentina, Australia, Colombia and more
- Nov 21, 2022Phase 3 study in Pneumococcal InfectionsMerck · NCT05633992 · 450 enrolled · Japan
- Jan 13, 2023Phase 3 study in Pneumococcal InfectionsMerck · NCT05696080 · 518 enrolled · United States, Australia, Canada and more
- Dec 11, 2023Phase 3 study in Pneumococcal InfectionsMerck · NCT06177912 · 882 enrolled · United States, Canada, Chile and more
- Oct 10, 2024Sanofi’s first study: phase 3 study in Pneumococcal InfectionsNew to SanofiSanofi · NCT06838000 · 1,268 enrolled · United States, Estonia, Poland and more
- Dec 11, 2024Phase 3 study in Pneumococcal ImmunizationSanofi · NCT06736041 · 1,714 enrolled · United States, Australia, Honduras and more
- Feb 7, 20252 phase 3 studies in Pneumococcal ImmunizationSanofi · NCT06824194, NCT06824181
- May 8, 2025Phase 3 study in Pneumococcal ImmunizationSanofi · NCT06975878 · 1,092 enrolled · Belgium, Czechia, Estonia and more
- Nov 19, 2025Phase 3 study in Anemia, Sickle CellSanofi · NCT07247188 · 100 planned · United States, Dominican Republic
- Jan 15, 2026Phase 3 study in Pneumococcal InfectionsSanofi · NCT07348692 · 2,195 planned · United States, Honduras, Puerto Rico and more
Ahead
- Dec 1, 2026Primary completion: phase 3 study in Pneumococcal InfectionsSanofi · NCT06838000
- Jan 7, 2027Primary completion: phase 3 study in Anemia, Sickle CellSanofi · NCT07247188
- May 17, 2027Primary completion: phase 3 study in Pneumococcal ImmunizationSanofi · NCT06736041
- Jun 7, 2027Primary completion: phase 3 study in Pneumococcal InfectionsSanofi · NCT07348692
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“A pneumococcal conjugate vaccine containing 21 different strains of the bacterium Streptococcus pneumoniae, that is used for the prevention of pneumococcal disease”NCIt, by rule
“Pneumococcal 21-Valent Conjugate Vaccine”name, by rule
Studies
All 18 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07348692Pneumococcal Infections · United States, Honduras, Puerto Rico and more | 3 | Recruiting | Sanofi | Jun 7, 2027 | 2,195 |
| NCT07247188Anemia, Sickle Cell · United States, Dominican Republic | 3 | Recruiting | Sanofi | Jan 7, 2027 | 100 |
| NCT06975878Pneumococcal Immunization · Belgium, Czechia, Estonia and more | 3 | Active, not recruiting | Sanofi | Aug 25, 2027 | 1,092 |
| NCT06824194Pneumococcal Immunization · United States, Honduras, Mexico and more | 3 | Active, not recruiting | Sanofi | Oct 22, 2027 | 2,360 |
| NCT06824181Pneumococcal Immunization · United States, Chile, Mexico and more | 3 | Active, not recruiting | Sanofi | Sep 10, 2027 | 580 |
| NCT06736041Pneumococcal Immunization · United States, Australia, Honduras and more | 3 | Active, not recruiting | Sanofi | May 17, 2027 | 1,714 |
| NCT06838000Pneumococcal Infections · United States, Estonia, Poland and more | 3 | Active, not recruiting | Sanofi | Dec 1, 2026 | 1,268 |
| NCT06177912Pneumococcal Infections · United States, Canada, Chile and more | 3 | Completed | Merck | Feb 26, 2025 | 882 |
| NCT05696080Pneumococcal Infections · United States, Australia, Canada and more | 3 | Completed | Merck | Feb 16, 2024 | 518 |
| NCT05633992Pneumococcal Infections · Japan | 3 | Completed | Merck | May 24, 2023 | 450 |
| NCT05569954Pneumococcal Infections · Argentina, Australia, Colombia and more | 3 | Completed | Merck | Oct 30, 2023 | 1,484 |
| NCT05526716Pneumonia, Pneumococcal · United States | 3 | Completed | Merck | Jun 21, 2023 | 1,080 |
| NCT05464420Pneumococcal Infections · United States, Austria, Canada and more | 3 | Completed | Merck | May 25, 2023 | 2,162 |
| NCT05425732Pneumococcal Infections · United States, Australia, Belgium and more | 3 | Completed | Merck | May 18, 2023 | 2,663 |
| NCT05420961Pneumonia, Pneumococcal · United States, Canada, France and more | 3 | Completed | Merck | May 16, 2023 | 717 |
| NCT05393037Pneumococcal Infections · United States, Belgium, Chile and more | 3 | Completed | Merck | Jul 13, 2023 | 313 |
| NCT04665050Pneumococcal Infections · Japan | 1 | Completed | Merck | Apr 6, 2021 | 102 |
| NCT04168190Pneumonia, Pneumococcal · United States | 2 | Completed | Merck | Jul 12, 2021 | 600 |
How it is read
Names in the registry
- “V116”, 11 entries
- “PCV21 vaccine”, 5 entries
- “PCV21”, 2 entries
Conditions, from the studies’ own filings
- Pneumococcal Infections, 10 studies
- Pneumonia, Pneumococcal, 3 studies
- Anemia, Sickle Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.